This indicates that the suppression of ZNF692 led to a decrease in tumor development in vivo. Subsequently, in order to further validate the impact of ZNF692 on MEK/ERK signaling via transcriptional regulation of TNK2, we assessed the levels of ZNF692 and TNK2 expression, as well as the degree of phosphorylation of MEK1/2 and ERK1/2 in the xenograft tumors. The gene discussed is MAPK3; the disease is neoplasm.